DYNAMICS OF CHANGES IN THE LEVELS OF MAIN FEMALE SEX HORMONES IN SERIAL APPLICATION OF 5-FLUORURACIL IN THE EXPERIMENT

Shamrai V. A., Misiurko O. I., Grebeniuk D. I., Taran I. V.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

5-fluorouracil is a widely used chemotherapeutic drug that has been used in medical practice for over 60 years and has become an integral part of chemotherapy for many cancers. Cytotoxicity of 5-fluorouracil is induced by preventing DNA replication and inhibition of RNA synthesis and manifests itself in the form of cardiotoxicity, neurotoxicity, gastrointestinal toxicity others. At the same time, the issue of ovarian toxicity is not fully covered in the modern scientific literature. The aim of the study was to study the dynamics of changes in the main female sex hormones with serial use of 5-fluorouracil in the experiment. The experiments were performed on 45 adult female white rats weighing 189.24±14.42 grams and under 1 year of age. The levels of antimullerian hormone, estradiol and follicle-stimulating hormone were studied. The levels of the studied hormones were studied by enzyme-linked immunosorbent assay. In total, 4 courses of chemotherapy were performed with an interval of 3 weeks. During each course of chemotherapy, 5-fluorouracil was administered at a dose of 83.7 mg/kg. After each course ofchemotherapy, the hormonal status of the experimental animals was studied twice: during the first proestrus after the course (to determine the acute ovarian toxicity of the drug) and during the last proestrus before the next course of chemotherapy (to study ovarian function restoration). The data obtained indicate an increase in the toxic effects of 5-fluorouracil during the study period, which is manifested by a progressive decrease in levels of antimullerian hormone and estradiol, as well as an increase in levels of follicle-stimulating hormone. The dynamics of the levels of studied sex hormones with serial administration of 5-fluorouracil is characterized by wavy dynamics with deterioration immediately after chemotherapy and partial recovery during the period between adjacent courses. Ovariotoxicity of 5-fluorouracil at serial administration in therapeutic doses in the experiment was manifested by significant changes in the levels of major female sex hormones only after the 4th course of chemotherapy

5-fluorouracil, ovariotoxicity, antimullerian hormone, estradiol, follicle-stimulating hormone, rats.

1. Ghafouri-Fard S, Abak A, Tondro Anamag F, Shoorei H, Fattahi F, Javadinia SA, et al. 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front Oncol. 2021;11:658636. DOI: 10.3389/ fonc.2021.658636.
2. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704. DOI: 10.1056/ NEJMoa071028.
3. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-1305. DOI: 10.1016/j.annonc.2020.06.022.
4. Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, et al. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol. 2019 Jul 10;37(20):1695-1703. DOI: 10.1200/JCO.18.02122.
5. Sakai M, Sohda M, Saito H, Kuriyama K, Yoshida T, Kumakura Y, et al. Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study. Cancer Chemother Pharmacol. 2019 Jun;83(6):1121- 1126. DOI: 10.1007/s00280-019-03835-0.
6. Ponce-Cusi R, Calaf GM. Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation. Int J Oncol. 2016 Feb;48(2):774-82. DOI: 10.3892/ijo.2015.3298.
7. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400. DOI: 10.1007/s11523-015-0402-9
8. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499- 508. DOI: 10.1016/S1470-2045(15)70127-0.
9. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 May 1;25(13):1658-64. DOI: 10.1200/JCO.2006.08.1620.
10. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol. 1994 Oct;12(10):2035-42. DOI: 10.1200/JCO.1994.12.10.2035.
11. Silverstein RA, González de Valdivia E, Visa N. The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6. Mol Cancer Res. 2011 Mar;9(3):332-40. DOI: 10.1158/1541-7786.MCR-10-0084.
12. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. DOI: 10.1177/1758835918780140.
13. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol. 2006 Jan;36(1):55-9. DOI: 10.1093/jjco/hyi214.
14. Fata F, Ron IG, Kemeny N, O’Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999 Oct 1;86(7):1129-34. DOI: 10.1002/(sici)1097-0142(19991001)86:7<1129::aid-cncr5>3.0.co;2-4.
15. Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction. 2012 Aug;144(2):153-63. DOI: 10.1530/ REP-12-0121.
16. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016 Oct;12(20):2333-44. DOI: 10.2217/fon-2016-0176.
17. Stringer JM, Swindells EOK, Zerafa N, Liew SH, Hutt KJ. Multidose 5-Fluorouracil is Highly Toxic to Growing Ovarian Follicles in Mice. Toxicol Sci. 2018 Nov 1;166(1):97-107. DOI: 10.1093/toxsci/kfy189.
18. Fu XY, Chen HH, Zhang N, Ding MX, Qiu YE, Pan XM, et al. Effects of chronic unpredictable mild stress on ovarian reserve in female rats: Feasibility analysis of a rat model of premature ovarian failure. Mol Med Rep. 2018 Jul;18(1):532-540. DOI: 10.3892/mmr.2018.8989.
19. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27-31. DOI: 10.4103/0976-0105.177703.
20. Naren G, Wang L, Zhang X, Cheng L, Yang S, Yang J, et al. The reversible reproductive toxicity of 5-fluorouracil in mice. Reprod Toxicol. 2021 Apr;101:1-8. DOI: 10.1016/j.reprotox.2021.02.002.

«Bulletin of problems biology and medicine» Issue 4 (162), 2021 year, 209-213 pages, index UDK 615.03 + 616-006 + 577.175.6

10.29254/2077-4214-2021-4-162-209-213